Cagrilintide / Retatrutide 5mg/5mg/3mL

What is Cagrilintide / Retatrutide?

This combination formulation pairs two of the most cutting-edge investigational compounds in metabolic research: Cagrilintide, a long-acting amylin analogue, and Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist. Together, they represent a multi-pathway approach to metabolic research that is generating significant scientific interest.

Researchers are exploring whether the complementary mechanisms of these two compounds may produce additive or synergistic effects on appetite regulation, energy expenditure, and metabolic function.

Mechanism of Action

This dual-compound formulation is being studied for its potential to influence:

• Amylin receptor activation (Cagrilintide) — mimics natural satiety signaling alongside insulin release
• Triple receptor agonism (Retatrutide) — simultaneously targets GLP-1, GIP, and glucagon receptors
• Multi-pathway appetite regulation — addresses satiety through both central and peripheral mechanisms
• Energy expenditure promotion — glucagon receptor activation may enhance caloric utilization

Areas of Research

Current studies are evaluating this combination's potential role in:

• Advanced obesity and weight management research
• Multi-mechanism metabolic therapy
• Appetite control and food intake reduction
• Glucose metabolism and insulin sensitivity

Research Use Only

This product is intended for laboratory research purposes only. It is not intended for human consumption, medical use, diagnosis, cure, mitigation, treatment, or prevention of any disease. This product has not been evaluated by the U.S. Food and Drug Administration (FDA). Purchasers are responsible for compliance with all applicable laws and regulations regarding the use and handling of research materials.